ADVM Live signaler | Maksimer profitt med Getagraph.com

KJøP 114082 min ago

@ $2.19

Utstedt: 14 feb 2024 @ 15:34

Avkastning: 376.71%

Forrige signal: feb 12 - 22:00

Forrige signal: Selg

Avkastning: 10.05 %

Live Chart Being Loaded With Signals

Commentary (3 mai 2024 @ 21:57):

Stats
Dagens volum	872 912
Gjennomsnittsvolum	330 547
Markedsverdi	216.68M
EPS	$0 ( 2024-04-04 )
Neste inntjeningsdato	( $-1.280 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.900
ATR14	$0.0180 (0.17%)

Insider Trading

Date	Person	Action	Amount	type
2023-10-03	Seyedkazemi Setareh	Buy	85 000	Stock Option (Right to Buy)
2023-10-03	Soparkar Peter	Buy	130 000	Stock Option (Right to Buy)
2023-10-03	Fischer Laurent	Buy	315 000	Stock Option (Right to Buy)
2024-02-12	Seyedkazemi Setareh	Buy	400 000	Stock Option (Right to Buy)
2024-02-12	Fischer Laurent	Buy	1 104 200	Stock Option (Right to Buy)

INSIDER POWER
97.18
Last 100 transactions
Buy: 14 665 896 \| Sell: 1 551 540

Volum Korrelasjon

Lang: 0.02 (neutral)

Kort: -0.92 (very strong negative)

Signal:(22.384) Possible Trading Opportunity Present (swing)

Adverum Biotechnologies Korrelasjon

10 Mest positive korrelasjoner
RVNC	0.965
VCNX	0.964
LYT	0.963
SBET	0.959
RSLS	0.957
HA	0.957
BCLI	0.956
FDMT	0.955
STKS	0.954
TNYA	0.953

10 Mest negative korrelasjoner
RMRM	-0.971
ACQR	-0.963
TBSA	-0.962
HERA	-0.962
NVSA	-0.961
FRSG	-0.961
LEGA	-0.96
FTPA	-0.96
GXII	-0.96
AGGR	-0.96

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Adverum Biotechnologies Korrelasjon - Valuta/Råvare

-0.56
( weak negative )

-0.61
( weak negative )

0.00
( neutral )

-0.26
( neutral )

-0.07
( neutral )

0.49
( neutral )

Adverum Biotechnologies Økonomi

Annual	2023
Omsetning:	$3.60M
Bruttogevinst:	$-2.04M (-56.78 %)
EPS:	$-11.62

FY	2023
Omsetning:	$3.60M
Bruttogevinst:	$-2.04M (-56.78 %)
EPS:	$-11.62

FY	2022
Omsetning:	$0
Bruttogevinst:	$-6.53M (0.00 %)
EPS:	$-15.57

FY	2021
Omsetning:	$0.00
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-1.709

Financial Reports:

No articles found.

Adverum Biotechnologies

Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.